8-Day Sell-Off Sends Regeneron Pharmaceuticals Stock Down -11%
Regeneron Pharmaceuticals (REGN) stock hit day 8 of a continuous streak of days with losses, with cumulative losses over this period amounting to a -11% return. The company has lost about $7.0 Bil in value over the last 8 days, with its current market capitalization at about $58 Bil. The stock remains 0.7% below its value at the end of 2024. This compares with year-to-date returns of 16.4% for the S&P 500.
Regeneron’s recent move stems from mounting Eylea biosimilar competition and a valuation downgrade, which collectively overshadowed robust Dupixent performance and promising pipeline data, including new gene therapy partnerships and multiple myeloma advancements. Investors are keenly focused on the biotech’s ability to navigate patent challenges and diversify its revenue streams.
What is the point? Sustained weakness can be more than noise. It often signals shifting sentiment or deeper concerns. A multi-day losing streak may warn of further downside, or present an opportunity to buy if fundamentals are intact. Our take: There are only a couple of things to fear in REGN stock given its overall Strong operating performance and financial condition. Considering stock’s Moderate valuation, we think it is Attractive (see Buy or Sell REGN).
For quick background, REGN provides innovative medicines worldwide, including treatments for eye diseases, atopic dermatitis, asthma, and rheumatoid arthritis through discovery, development, manufacturing, and commercialization.
Comparing REGN Stock Returns With The S&P 500
The following table summarizes the return for REGN stock vs. the S&P 500 index over different periods, including the current streak:
| Return Period | REGN | S&P 500 |
|---|---|---|
| 1D | -2.1% | -0.3% |
| 8D (Current Streak) | -10.7% | 1.2% |
| 1M (21D) | 8.9% | 1.9% |
| 3M (63D) | 26.5% | 5.1% |
| YTD 2025 | -0.7% | 16.4% |
| 2024 | -18.9% | 23.3% |
| 2023 | 21.7% | 24.2% |
| 2022 | 14.2% | -19.4% |
Take a look at what history tells you about whether past dips like this have been buying opportunities or traps: REGN Dip Buyer Analysis.
Gains and Losses Streaks: S&P 500 Constituents
There are currently 53 S&P constituents with 3 days or more of consecutive gains and 104 constituents with 3 days or more of consecutive losses.
| Consecutive Days | # of Gainers | # of Losers |
|---|---|---|
| 3D | 8 | 52 |
| 4D | 22 | 14 |
| 5D | 20 | 6 |
| 6D | 0 | 22 |
| 7D or more | 3 | 10 |
| Total >=3 D | 53 | 104 |
Key Financials for Regeneron Pharmaceuticals (REGN)
Last 2 Fiscal Years:
| Metric | FY2023 | FY2024 |
|---|---|---|
| Revenues | $13.1 Bil | $14.2 Bil |
| Operating Income | $4.2 Bil | $4.1 Bil |
| Net Income | $4.0 Bil | $4.4 Bil |
Last 2 Fiscal Quarters:
| Metric | 2025 FQ2 | 2025 FQ3 |
|---|---|---|
| Revenues | $3.7 Bil | $3.8 Bil |
| Operating Income | $1.1 Bil | $1.1 Bil |
| Net Income | $1.4 Bil | $1.5 Bil |
The losing streak REGN stock is currently on doesn’t inspire much confidence among investors. In contrast, Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 — the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.